UCB 29936

Drug Profile

UCB 29936

Latest Information Update: 26 May 2005

Price : $50

At a glance

  • Originator UCB
  • Class Antiasthmatics
  • Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Asthma; Septic shock

Most Recent Events

  • 26 May 2005 Discontinued - Preclinical for Asthma in Europe (unspecified route)
  • 26 May 2005 Discontinued - Preclinical for Septic shock in Belgium (Injection)
  • 17 Jan 2000 Preclinical development for Septic shock in Belgium (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top